Long timelines, high costs, and uncertainty over the probability of success in new drug development
First written in FY2021. 10 of 21 entries say "Worsened", first in FY2022-Q2. Latest entry: 2026-08-13.
Perseus Proteomics moved to the "Worse" side of this theme in 2021, 1 year after the typical company in this theme (2020).
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
4 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the value in use of assets related to the business at zero and recognized the ¥37.260 million difference between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
Although the impairment loss attributable to uncertainty regarding future income continued, the amount decreased from ¥72.510 million in the previous fiscal year to ¥37.260 million. - FY2026-H1MitigatedAnnual report
「An impairment loss of ¥32.838 million was recognized under extraordinary losses. Given the characteristics of our business and the high uncertainty regarding future income at this stage, the recoverable amount of fixed assets related to the pharmaceutical business was assessed at zero, and the impairment loss comprised the difference between the carrying value and the memorandum value plus the amount determined to be unrecoverable from estimated restoration costs included in security deposits.」
Although the impairment loss attributable to uncertainty regarding future income continued, the amount decreased from ¥66.959 million in the same period of the previous year to ¥32.838 million. This included ¥28.299 million resulting from a change in the estimate of restoration costs. - FY2025MitigatedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of assets related to the business at zero and recognized the difference of ¥72.510 million between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
Although the impairment loss attributable to uncertainty regarding future income continued, the amount decreased from ¥153.887 million in the previous fiscal year to ¥72.510 million. - FY2025-H1MaterialisedAnnual report
「An impairment loss of ¥66.959 million was recognized under extraordinary losses because, given the characteristics of our business and the high uncertainty regarding future income at this stage, the recoverable amount of fixed assets related to the pharmaceutical business was assessed at zero and the difference between the carrying value and the memorandum value was recognized as an impairment loss.」
An impairment loss of ¥66.959 million related to fixed assets of the pharmaceutical business was actually recognized because of uncertainty regarding future income. - FY2024WorsenedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of assets related to the pharmaceutical business at zero and recognized the difference of ¥153.887 million between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
The impairment loss in pharmaceutical business assets attributable to uncertainty regarding future income increased to ¥153.887 million, from ¥95.468 million in the previous fiscal year. - FY2024-Q3WorsenedAnnual report
「An impairment loss of ¥146.970 million was recognized under extraordinary losses because, given the characteristics of our business and the high uncertainty regarding future income at this stage, the recoverable amount of fixed assets related to the pharmaceutical business was assessed at zero and the difference between the carrying value and the memorandum value was recognized as an impairment loss.」
The impairment loss in pharmaceutical business assets attributable to uncertainty regarding future income increased to ¥146.970 million, exceeding ¥134.208 million in the cumulative previous quarter. - FY2024-Q2WorsenedAnnual report
「An impairment loss of ¥134.208 million was recognized under extraordinary losses because, given the characteristics of our business and the high uncertainty regarding future income at this stage, the recoverable amount of fixed assets related to the pharmaceutical business was assessed at zero and the difference between the carrying value and the memorandum value was recognized as an impairment loss.」
The impairment loss in pharmaceutical business assets attributable to uncertainty regarding future income increased to ¥134.208 million, exceeding ¥95.468 million at the end of the previous fiscal year and ¥73.481 million in the same period of the previous year. - FY2024-Q1WorsenedAnnual report
「An impairment loss of ¥129.845 million was recognized under extraordinary losses because, given the characteristics of our business and the high uncertainty regarding future income at this stage, the recoverable amount of fixed assets related to the pharmaceutical business was assessed at zero and the difference between the carrying value and the memorandum value was recognized as an impairment loss.」
An impairment loss of ¥129.845 million related to pharmaceutical business assets was recognized because of uncertainty regarding future income, an increase from ¥95.468 million at the end of the previous fiscal year. - FY2023RestatedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the value in use of the recoverable amount of assets related to the business at zero and recognized the ¥95.468 million difference between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
Because of uncertainty regarding future income, the recoverable amount of pharmaceutical business assets was assessed at zero and an impairment loss of ¥95.468 million was recognized. - FY2023-Q3WorsenedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of assets related to the pharmaceutical business at zero, reduced their carrying value to the memorandum value, and recognized the resulting difference of ¥92.495 million as an impairment loss.」
The impairment loss in the pharmaceutical business attributable to uncertainty regarding future income increased to ¥92.495 million, from ¥73.481 million in the cumulative previous quarter. - FY2023-Q2WorsenedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of fixed assets related to the pharmaceutical business at zero and recognized the difference of ¥73.481 million between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
An impairment loss of ¥73.481 million related to the pharmaceutical business was recognized because of uncertainty regarding future income, indicating that the risk continued to materialize during the cumulative current quarter following ¥117.813 million at the end of the previous fiscal year. - FY2023-Q1WorsenedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of fixed assets related to the pharmaceutical business at zero and recognized the difference of ¥55.020 million between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
An impairment loss of ¥55.020 million related to the pharmaceutical business was recognized in the current quarter because of uncertainty regarding future income. This exceeded the ¥5.817 million recognized in the same period of the previous year. - FY2022WorsenedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of assets related to the pharmaceutical business at zero and recognized the difference of ¥117.813 million between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
The impairment loss attributable to uncertainty regarding future income increased to ¥117.813 million, from ¥22.079 million in the cumulative previous quarter. - FY2022-Q3WorsenedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of fixed assets related to the pharmaceutical business at zero, reduced their carrying value to the memorandum value, and recognized the resulting difference of ¥22.079 million as an impairment loss.」
The impairment loss in the pharmaceutical business attributable to uncertainty regarding future income increased to ¥22.079 million, from ¥9.316 million in the cumulative previous quarter. - FY2022-Q2WorsenedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of the carrying value of fixed assets related to the pharmaceutical business at zero and recognized the difference of ¥9.316 million between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
The impairment loss in the pharmaceutical business attributable to uncertainty regarding future income increased from ¥5.817 million in the cumulative previous quarter to ¥9.316 million. - FY2022-Q1MaterialisedAnnual report
「Given the characteristics of our business and the high uncertainty regarding future income at this stage, we assessed the recoverable amount of the carrying value of fixed assets related to the pharmaceutical business at zero and recognized the difference of ¥5.817 million between the carrying value and the memorandum value as an impairment loss under extraordinary losses.」
An impairment loss of ¥5.817 million was actually recognized on fixed assets related to the pharmaceutical business because of uncertainty regarding future income. - FY2021First statedAnnual report
「Even if a novel antibody therapeutic candidate expected to be highly effective in basic research and nonclinical studies is identified, development may be delayed, or the research and development plan may be postponed or discontinued, if the expected efficacy is not achieved in subsequent clinical trials, serious adverse effects occur, or approval is not obtained in the regulatory review process.」
Identifying the possibility of development delays, postponement, or discontinuation due to clinical efficacy, safety, or regulatory approval as a key risk.